Join the Atopic Dermatitis group to help and get support from people like you.
Atopic Dermatitis News (Page 2)
Related terms: Atopic Eczema, Dermatitis, Atopic, Discoid Eczema, Infantile Eczema
Both Ciclosporin, Methotrexate Effective for Severe Eczema in Children
TUESDAY, Sept. 26, 2023 – For children and young people with severe atopic dermatitis (AD), ciclosporin (CyA) and methotrexate (MTX) are both effective over 36 weeks, according to a study published...
Atopic Dermatitis Increases Risk for Inflammatory Bowel Disease
THURSDAY, Aug. 31, 2023 – Both children and adults with atopic dermatitis have an increased risk for inflammatory bowel disease (IBD), according to a study published online Aug. 30 in JAMA...
Dupilumab Treatment Beneficial for Sleep in Atopic Dermatitis
TUESDAY, Aug. 22, 2023 – For adults with moderate-to-severe atopic dermatitis (AD), dupilumab treatment yields significant improvement in sleep quality and other AD-related signs and symptoms,...
Higher Risk for Schizophrenia Seen Among Patients With Eczema
TUESDAY, Aug. 8, 2023 – Having atopic dermatitis is associated with a higher risk for schizophrenia and schizoaffective disorder, according to a study published online July 26 in the Archives of...
Prevalence of Atopic Diseases Increased in Sexually Diverse Individuals
WEDNESDAY, July 12, 2023 – The prevalence of atopic diseases, including atopic dermatitis, is increased in sexually diverse people, including those who identify as lesbian, gay, or bisexual,...
Crisaborole Effective for Long-Term Maintenance in Mild-to-Moderate Eczema
WEDNESDAY, June 28, 2023 – Crisaborole is effective as a long-term maintenance therapy for pediatric and adult patients with mild-to-moderate atopic dermatitis (AD), according to a study published...
Atopic Dermatitis Tied to Higher Venous Thromboembolism Risk
WEDNESDAY, May 31, 2023 – Atopic dermatitis (AD) in adulthood is associated with an increased risk for venous thromboembolism (VTE), according to a study published online May 31 in JAMA Dermatology....
FDA Approves Pfizer's Supplemental New Drug Application for Cibinqo (abrocitinib) to Include Adolescents with Moderate-to-Severe Atopic Dermatitis
Label expansion for Cibinqo provides new systemic oral option for adolescents (12 to
FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood Children treated with Dupixent and topical corticosteroids (TCS)...
FDA Approves Cibinqo (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
NEW YORK--(BUSINESS WIRE) January 14, 2022 – Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Cibinqo® (abrocitinib), an oral, ...
FDA Approves Adbry (tralokinumab-ldrm) for Adults with Moderate-to-Severe Atopic Dermatitis
MADISON, N.J.--(BUSINESS WIRE) December 28, 2021 --LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab-ldrm) for the treatment of m...
FDA Approves Opzelura (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD)
WILMINGTON, Del.--(BUSINESS WIRE) September 21, 2021 – Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream for the s...
FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
TARRYTOWN, N.Y. and PARIS, May 26, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupi...
FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with...
FDA Approves Dupixent (dupilumab) for Eczema
March 28, 2017 – The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
prednisone, methylprednisolone, clobetasol, fluocinonide, Dupixent, dexamethasone, desonide, halobetasol